Purchase Order 75N95021P00653

The National Institute on Drug Abuse awarded a $1.4 million contract to The Emmes Company LLC to provide integrated care and treatment for severe infectious diseases and substance use disorders among hospitalized patients under Clinical Trials Network study CTN-0121 from September 2022 through February 2026. As the prime contractor, The Emmes Company LLC will conduct the clinical trial and data, statistics, and clinical trial support for this study exploring coordinated treatment approaches...

The National Institute on Drug Abuse awarded a $1.25 million delivery order contract to The Emmes Company LLC under its Data, Statistics, and Clinical Trial Support Center indefinite delivery/indefinite quantity contract vehicle. The cost plus fixed fee contract is for the Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone clinical trial and will run from September 2019 through April 2023. As the prime contractor, The Emmes Company will provide data management, biostatistical...

This is a $499,770 firm fixed price task order awarded by the Food and Drug Administration (FDA) to Research Triangle Institute (RTI International), a non-profit research organization, to conduct a patient preference study on opioid use disorder (OUD). The objective is to better understand the perspectives of patients, family members, and healthcare providers affected by OUD. This task order was issued under RTI's existing Multiple Award Schedule (MAS) contract with the Environmental...

This is a cost-plus-fixed-fee delivery order under the Research, Measurement, Assessment, Design, and Analysis 2 (RMADA 2) indefinite delivery vehicle, awarded by the Centers for Medicare and Medicaid Services (CMS) to the non-profit research organization Research Triangle Institute (RTI International). The $2,071,301.00 contract is for the evaluation of an opioid use disorder treatment demonstration. The contract does not have a set-aside designation. RTI International, as the prime contractor,...

This is a $983,066 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization, to conduct a bioequivalence study of lamotrigine extended release tablets. The delivery order was issued against an existing $21 million single-award indefinite delivery contract with the National Institute on Drug Abuse (NIDA) for pharmacokinetic and pharmacodynamic trials to develop medications for substance use...

This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO). The $1,340,461.88 firm fixed-price delivery order is for a clinical trial to assess the safety, tolerability, and pharmacokinetics of an investigational agent for substance use disorder (SUD) treatment. The contract is part of NIDA's $21 million indefinite delivery contract N01DA-23-8935, which supports...

This is a $1,484,606.68 definitive contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan to conduct research and analysis on stimulant use, misuse, and use disorder trajectories. The contract has no set-aside designation. Under the contract, the University of Michigan will coordinate with Massachusetts General Hospital and Texas State University to supplement existing drug use and health survey data with clinical data from the MGH's HEAL project....

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of 15mg amphetamine mixed salts extended-release capsules, a controlled substance medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $4,920.42 and a completion date of August 12, 2024. It is a firm-fixed-price delivery order contract, with no...

This federal contract award, with an ID of 75N95019D00013|75N95020F00004, was issued by the National Institute on Drug Abuse (NIDA) to The Emmes Company LLC, a global clinical research organization based in Rockville, Maryland. The contract supports the PRIMARY CARE OPIOID USE DISORDERS TREATMENT TRIAL (CTN-0074) from 9/1/2020 to 12/31/2021, with a potential completion date of 8/31/2022. The contract is a Delivery Order valued at $215,775.68 with a Cost Plus Fixed Fee pricing type. The Emmes...

This $200,000.00 firm fixed-price Delivery Order was awarded by the Agency for Healthcare Research and Quality (AHRQ) to Oregon Health & Science University (OHSU) on December 14, 2015. The contract was issued under AHRQ's Evidence-based Practice Centers (EPC V) indefinite delivery vehicle and does not have a set-aside designation. The purpose of the contract is to provide a TECHNICAL BRIEF on MEDICATION-ASSISTED TREATMENT PROGRAMS. As a prominent research university and academic medical...